Five things to know:
1. Quarterly sales rose 4.7% year over year.
2. Medtronic’s cranial and spinal technologies segment saw $1.2 billion in quarterly sales, an increase of 6.7% year over year.
3. The company’s full neuroscience portfolio saw $2.3 billion in sales, up 4.8% year over year.
4. Medtronic’s medical surgical portfolio grew 3.9% year over year with $2.1 billion in sales. The cardiovascular portfolio netted $2.9 billion in sales, a 6.1% increase year over year.
5. Medtronic raised its guidance for fiscal year 2024 and expects to see full-year growth of 4.75% to 5% year over year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
